Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication
Abstract
   Non-enzymatic glycosylation (glycation) plays an important role in the development of physiological and pathophysiological processes such as aging, diabetes, atherosclerosis, neurodegenerative diseases and chronic renal failure. Preventing glycation can minimize diabetic complications. Glycation can be prevented by the natural defence system in the body, synthetic inhibitors and natural inhibitors. Synthetic inhibitors may prevent glycation through several possible mechanisms. They might inhibit the glycation by interfering with the attachment of sugars with proteins, by inhibiting the late stage of glycation or by preventing Amadori product formation. Furthermore, their ability to scavenge free radicals and to break cross-links might be other mechanisms responsible for their potential to inhibit glycation. Naturally occurring phytochemicals/products have been found to be relatively non-toxic as compared to synthetic compounds, and are inexpensive and available in an ingestible form. A large number of plants and natural biomolecules have been shown to have antidiabetic effects. Several hypoglycaemic compounds have anti-oxidant properties. The present review describes the various ways in which glycation can be prevented.
Key words: Glycation, diabetic complications, natural defence system, synthetic inhibitors, natural inhibitors
Abbreviations: AGEs, advanced glycation end products; ROS, reactive oxygen species; GSH, gluthathione; MG, methyglyoxal; RNS, reactive nitrogen species; AG, aminoguanidine; ARIs, Aldose reductase inhibitors.